m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer
- 1 October 1994
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 70 (4) , 753-758
- https://doi.org/10.1038/bjc.1994.390
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- RECOMBINANT HUMAN-MOUSE CHIMERIC MONOCLONAL-ANTIBODY SPECIFIC FOR COMMON ACUTE LYMPHOCYTIC-LEUKEMIA ANTIGEN1987
- Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.Proceedings of the National Academy of Sciences, 1987
- The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodiesInternational Journal of Cancer, 1986
- Mechanisms of tumor growth inhibition.1986
- Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.The Journal of Immunology, 1986
- The interaction of murine IgG subclass proteins with human monocyte Fc receptors.The Journal of Immunology, 1985
- THE CHARACTERISTICS OF BLOOD-BORNE RADIOLABELS AND THE EFFECT OF ANTI-MOUSE IGG ANTIBODIES ON LOCALIZATION OF RADIOLABELED MONOCLONAL-ANTIBODY IN CANCER-PATIENTS1985
- Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.Proceedings of the National Academy of Sciences, 1984
- Monoclonal antibodies in cell‐mediated cytotoxicity against human melanoma and colorectal carcinomaEuropean Journal of Immunology, 1979
- Antibody-dependent cell-mediated cytotoxicity in treated and nontreated cancer patientsCancer, 1977